U.S. markets closed
  • S&P Futures

    4,216.00
    +6.25 (+0.15%)
     
  • Dow Futures

    33,338.00
    +34.00 (+0.10%)
     
  • Nasdaq Futures

    13,341.25
    +30.00 (+0.23%)
     
  • Russell 2000 Futures

    1,979.90
    +3.60 (+0.18%)
     
  • Crude Oil

    93.87
    -0.47 (-0.50%)
     
  • Gold

    1,804.50
    -2.70 (-0.15%)
     
  • Silver

    20.29
    -0.06 (-0.29%)
     
  • EUR/USD

    1.0318
    -0.0007 (-0.07%)
     
  • 10-Yr Bond

    2.8880
    +0.1020 (+3.66%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2192
    -0.0010 (-0.08%)
     
  • USD/JPY

    133.3190
    +0.3200 (+0.24%)
     
  • BTC-USD

    23,992.69
    -265.09 (-1.09%)
     
  • CMC Crypto 200

    570.35
    -4.39 (-0.76%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,479.99
    +660.66 (+2.37%)
     

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Cocrystal Pharma Inc (NASDAQ: COCP) has selected two investigational novel antiviral drug candidates for further development as oral treatments for COVID-19.

  • CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.

  • Cocrystal plans to initiate a first-in-human trial with one selected candidate as soon as possible this year.

  • Although CDI-988 and CDI-873 are chemically differentiated, both exhibited superior in vitro potency against SARS-CoV-2 with activity maintained against current variants of concern, including omicron.

  • Related: Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant.

  • Both candidates demonstrated a favorable safety profile and pharmacokinetic properties in preclinical studies supportive of daily oral dosing.

  • "In addition to initiating two COVID-19 trials in 2022, we anticipate completion of our influenza CC-42344 Phase 1 study this year," said James Martin, Cocrystal's CFO and interim co-CEO.

  • Cocrystal received guidance from the FDA for further development of CDI-45205 in response to the Company's pre-Investigational New Drug (IND) briefing package.

  • Price Action: COCP shares are up 0.56% at $0.51 during the market session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.